WJ01024 + Ruxolitinib combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-30 — A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis: Phase Ib/II trial (trial-early): WJ01024 (novel investigational agent, mechanism undisclosed) being evaluated in combination with ruxolitinib in medium-to-high-risk MF patients with splenomegaly who had poor response (Group A) or intolerance (Group B) to approved JAK inhibitors — dose-escalation followed by efficacy expansion, assessing safety, efficacy, and pharmacokinetics in the JAKi-refractory/intolerant population. (novelty: 3)
Open questions
Related
Contributing findings
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
30-mar-2026
novelty 3
per-area 3
introduces